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Summary The expression of TGF-x in human colon and lung carcinoma cell lines has been reported
previously, but its expression in primary tumours has not been described in detail. We have used the
radio-immunoassay method to measure the specific content of immunoreactive TGF-x in the acid ethanol
extracts of normal and cancerous tissues of human colon and lung. The average TGF-a content of colon
carcinomas is 4 times that of the normal mucosa, and for non-small cell lung carcinomas it is twice that of the
normal parenchyma. Because of variability in the TGF-x expression among individuals and in different
segments of colon and lobes of lung, the ratio of TGF-a content of paired tumour and normal tissue was also
calculated. On average, the tumour/normal ratio for colon carcinoma is higher than that for lung carcinoma.
Although 55% of colon tumours show a ratio 4 times, or greater, only 33% of lung carcinomas demonstrate
this ratio. The level of TGF-a in both colon and lung carcinomas does not correlate with histological type,
stage, grade nor degree of desmoplasia of these tumours. Northern blot analysis of total cellular RNA
confirms the expression of an approximately 4.8 kb TGF-a mRNA in normal colonic mucosa and lung
parenchyma. However, in contrast to the results of radio-immunoassay, significant over-expression of TGF-x
mRNA is uncommon in primary human colon carcinomas.
Transforming growth factor-alpha (TGF-a) was first isolated
and identified as one of the components of the sarcoma-
derived growth factor that interacted with the receptor of
epidermal growth factor (EGF) (Delarco & Todaro, 1978;
Anzano et al., 1983). Subsequent investigations revealed that
the TGF-a molecule shared approximately 40% homology to
the amino acid sequence of EGF (Marquardt et al., 1983;
Marquardt et al., 1984), and it appeared to exert its bio-
logical effects exclusively by interacting with the EGF recep-
tors (Carpenter et al., 1983). The initial findings of frequent
expression of TGF-a in neoplastic or malignant but not in
normal cell lines nor adult tissues, coupled with the demon-
stration of its expression in fetal/embryonic tissues in rats
led to the suggestion that TGF-a represented an oncofetal
counterpart of EGF (Goustin et al., 1986). Recently, the
expression of TGF-x has been demonstrated in several
human normal adult cells/tissues including skin keratinocytes
(Coffey et al., 1987b), breast ductal epithelial cells (Zajchow-
ski et al., 1988), activated macrophages (Madtes et al., 1988;
Rappolee et al., 1988), gastrointestinal mucosa (Bennett et
al., 1989; Cartlidge & Elder, 1989), and kidney (Gomella et
al., 1989). TGF-a expression by human colonic and lung
carcinoma cell lines has been reported previously (Coffey et
al., 1987a; Hanauske et al., 1987; Watkins et al., 1988;
Anzano et al., 1989; Derynck et al., 1987) but its expression
and possible biological role in primary human lung and
colonic carcinomas has not been studied systematically. We
have used both the radioimmunoassay and nucleic acid hyb-
ridisation techniques to examine the expression of TGF-a in
primary human colonic and lung carcinomas.
Materials and methods
Human colon and lung carcinoma tissues were obtained
within 30 to 60 min after surgical resection. When enough
tissue was available, grossly normal colonic mucosa at least
10 cm away from the edge of tumour and the posterior basal
segment of the lobectomy specimen from each case was
concurrently obtained and used as the paired 'normal/con-
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trast' tissue. Some normal mucosa, from colons resected for
diverticular disease, was also obtained. The specimens were
snap-frozen in liquid nitrogen and then stored at -80'C.
Extraction of TGFfrom tissues
The acid ethanol extraction procedure for tissue growth fac-
tors was performed exactly according to Roberts et al.
(1980). The final extracts were dialysed in distilled water,
lyophilised and then reconstituted with 4mM HCI.
Radioimmunoassay (RIA)
This was performed using a kit from BioTope (Seattle,
Washington) and according to the instructions provided by
the manufacturer. The antibody was rabbit anti-rat TGF-a
antiserum which recognised both the high and low molecular
weight forms of rat and human bio-active TGF-a. We have
independently confirmed its non-cross reactivity with EGF. A
standard curve was established using varying concentrations
of synthetic mature rat TGF-x (BioTope, M.W. 5600) and
100fsg of extract protein from each sample was used for the
assay. Measurements were conducted in duplicate and non-
specific binding was measured for each sample by replacing
the antibody with pre-immune serum. All values were repre-
sented as nanogram equivalents of mature TGF-a per 100 1sg
protein.
RNA extraction and electrophoresis
Approximately 1 g of frozen tissue was cut into 2-3 mm
cubic fragments and homogenised by a Brinkman's Polytron
in 6 ml solution containing 4 M guanidine isothiocyanate,
pH 7.0, 25 mM sodium citrate, 0.1 M P-mercaptoethanol and
0.5% sarkosyl. The homogenate was layered onto a 3.3 ml
cushion of 5.7M CsCI solution, pH 5.0, containing 25 mM
sodium acetate in an 11 ml polyallomer tube, and centrifuged
at 32,000 r.p.m. for 20 h at room temperature. The clear
gelatinous pellet of RNA was dissolved in distilled water
pretreated with diethylpyrocarbonate (depc-dH2O) containing
0.3 M sodium acetate. After one extraction with equal
volumes of phenol and chloroform, the aqueous phase con-
taining the RNA was precipitated at - 70°C with 3 volumes
of 95% ethanol. After a 15 min centrifugation at 12,000g,
the pellet was redissolved in depc-H20 and the amount of the
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total RNA was estimated by measuring the absorbence at
260 nm.
Thirty jLg of the total RNA sample was denatured at 65°C
for 10 min in a solution containing 20 mM MOPS, 50%
formamide and 6% formaldehyde, and was separated electro-
phoretically in 1% agarose gel containing 0.66 M formal-
dehyde and in 20 mM MOPS running buffer that contained
5 mM sodium acetate and I mM EDTA, pH 7.0. The RNA
was blotted on to Hybond-N membrane (Amersham Canada,
Oakville, Ont.) with 20 times standard saline citrate
(20XSSC; 1XSSC: 0.1 M sodium chloride/0.015 M sodium cit-
rate, pH 7.0). The air-dried membrane was exposed to the
ultraviolet light of UV-transilluminator for 1 min to cross-
link the RNA to the membrane.
Hybridisation
This was performed according to a slightly modified proce-
dure of Church & Gilbert (1984). The probe for TGF-a was
a 2.3 kb-pairs EcoRI insert of the prTGF0.2 plasmid contain-
ing the rat TGF-a cDNA (Lee et al., 1985) which shares
approximately 90% homologous nucleotides with the coding
sequences of the human TGF-o gene (Derynck et al., 1984).
Probes were labelled with [32P]-dCTP (ICN Canada, Mon-
treal, Que.) to high specific activity (approximately 109 c.p.m.
g-') using the Oligolabelling kit of Pharmacia (Dorval,
Que.). Membranes were prehybridised at 42°C for 1-2 h in a
solution containing 0.5 M NaPHO4, pH 7.2, 5% BSA fraction
V, 1 mM EDTA and 5% sodium dodecyl sulphate and 50%
deionised formamide. Hybridisation was carried out in the
same solution containing 32P-labelled probes at 42°C for 48 h.
The membrane was sequentially washed 4 times for 15 min at
room temperature in 2XSSC solution containing 0.1% SDS,
and twice for 30 min at 55°C in 0.3XSSC solution containing
0.1 % SDS. After a final rinse in IXSSC, the membrane was
blotted dry and exposed for 5-8 days at -80°C to XAR-5
Kodak X-ray film using an intensifying screen. Densitometric
measurements were performed using the Hoefer GS-300 scan-
ning densitometer. All TGF-a values were standardised with
the level of P-actin expression as probed by cDNA from the
3'-untranslated region of human P-actin gene (Ponte et al.,
1983).
Pathological evaluation
The pathology was reviewed without knowing the results of
the biochemical measurements. In most cases, slides from 2
to 4 sections of the tumours were available for examination
by one of us (MST). Classification of the histological type
and degree of differentiation (grade) of tumours was based
on the predominant finding observed.
Statistical analysis
All statistical analyses were performed using the non-para-
metric Wilcoxon rank sum test for independent samples
(McClare & Dietrich, 1988). In some cases, Student's t-test
was also performed.
Results
Although there was considerable variations among individ-
uals (Figure 1), the acid ethanol extracts of both normal
colonic mucosa and lung parenchyma contained approxi-
mately 0.8 ng immunoreactive TGF-a per 100 jig protein
(Tables I and II). The mean TGF-a value for the right
(caecum, ascending and transverse) colon was 1.19±0.30,
and for the left (descending, sigmoid and rectal) colon was
0.55 ± 0.20, but this difference is statistically insignificant.
The amount ofimmuno-reactive TGF-o in extracts of normal
mucosa of colons resected for diverticular disease was not
significantly different from that of 'normal' mucosa of can-
cerous colons.
Adenocarcinomas of the colon contained approximately 4
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Figure 1 The specific content of immunoreactive TGF-a in acid
ethanol extracts of paired tumour and normal tissues of patients
with colon and lung carcinomas.
Table I TGF-a levels in acid ethanolextracts ofnormal and malignant
human colonic epithelium
Normal Tumour P value
Means of
Total 0.83± 0.18 (25) 3.40± 1.21 (29) <0.001
Right colon 1.19±0.30 (11) 2.24±0.24 (10) <0.005
Left colon 0.55±0.20 (14) 4.02±2.00 (19) <0.001
Duke's staging:
A - 2.44±0.13 (2) NS B _ 4.05±2.10 (18) NS
C - 2.29±0.52 (9)
Desmoplasia:
Slight - 15.12± 12.04 (3)
Moderate - 1.70±0.24 (19)
Marked - 3.03± 1.01 (6) NS
Differentiation:
Well - 2.15±0.36 (12) NS
Moderate - 4.92± 2.68 (14)
Poor - 0.55±0.37 (2)
Inflammatory reaction:
Sparse - 2.50± 0.20 (15) NS Moderate/severe - 4.47±2.91 (13)
All values represent means±s.e. in ng per 100jig protein; ( ): the
number ofspecimens; NS: not statistically significant.
Table II TGF-a levels in acid ethanol extracts of normal and
malignant human lung tissues
Normal Tumour P value
Means of.
All specimens 0.84±0.19 (18) 1.79±0.21 (16) <0.002
Upper lobes 0.52± 0.18 (10) NS Middle & lower 1.25±0.33 (8)
lobes
Histological types:
Epidermoid 1.45±0.37 (5)
carcinoma NS
Adenocarcinoma 1.74±0.37 (7) NS
Large cell 2.29± 0.53 (4)
carcinoma
Desmoplasia:
Slight 2.07±0.59 (4) NS
Moderate/severe 1.70±0.21 (12)
Lymph node metastasis:
Negative 1.57±0.22 (10) NS Positive 1.81 ±0.30 (5)
All values represent means±s.e.; ( ): number of specimen studied;
NS: not statistically significant.
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times higher immunoreactive TGF-c than normal colonic
mucosa (Table I). There was no difference in the values for
tumours of the right versus left colon. One of the left colonic
tumours demonstrated an unusually high TGF-a content
(39.2ng per 100 lg protein), and when this specimen is ex-
cluded, the mean TGF-x content of the remaining left colonic
tumour was 2.08 ± 0.42, which is not significantly different
from the mean value for right-sided tumours. The TGF-a
content of the tumour cannot be correlated to the stage of
the disease, to the differentiation (grade) of the tumours, or
to the degree of inflammatory response present in the
tumours. Although tumours with marked desmoplasia dem-
onstrated higher TGF-a values than those with moderate
desmoplasia, there is no significant difference between these
tumours and those with slight desmoplasia. There were not
enough specimens to evaluate the significance of a low TGF-
a value in poorly-differentiated carcinomas. Interestingly, the
specimen with an unusually high TGF-a content shows only
slight desmoplastic reaction.
Immunoreactive TGF-a was also consistently measurable
in acid ethanol extracts of normal lung parenchyma and the
level is approximately twice as high in the lower and middle
lobes than in the upper lobes, but the difference is also not
statistically significant (Table II). In contrast to colon
cancers, lung carcinomas demonstrated only about twice as
much TGF-a as the normal lung parenchyma. A significant
statistical difference was not found between the different
histological types of lung carcinomas, the degree of desmo-
plasia and the stage of the disease (Table II).
Since the TGF-a content among individual patients varied
considerably, we also calculated the ratio of TGF-a content
of tumour versus normal tissue among specimens with paired
samples. The mean of tumour/normal (T/N) ratio for colon
carcinomas was 4 times higher than that of lung carcinomas
(Table III). The distribution of these T/N ratios is shown in
Figure 2. Among colon carcinomas, left-sided tumours gave
a significantly higher mean ratio than the right-sided
tumours; 55% of colonic carcinomas have a T/N ratio higher
than 4, whereas only 33% of lung carcinomas demonstrated
this high ratio. However, this difference is not statistically
significant by Yates corrected x2 test, or Fisher exact test.
Northern blot analyses of total RNA extracted from nor-
mal colonic mucosa and lung parenchyma consistently dem-
onstrate the presence of an approximately 4.8 kb mature
TGF-o mRNA in these tissues (Figure 3). However, in con-
trast to the radio-immunoassay findings, the relative expres-
sion of TGF-x mRNA in colon carcinomas is rarely much
more than that of the contrasting normal mucosa (Figure 4).
Fewer than 20% of these tumours expressed 2 to 3 times
more TGF-a mRNA than their corresponding normal
mucosa. However, in 2 of 5 tumours whose TGF-x mRNA
levels were twice as much, or more, than their contrasting
normal mucosa, immunoreactive TGF-a content was also
measured and found to be very high, indicating good correla-
tion between high mRNA expression level and high level of
TGF-a peptide in tumour tissues. A comparative study
indicates that the level of TGF-a mRNA expression in these
colonic tumours or normal mucosa is approximately one
hundredth of that expressed by HT-29 colon carcinoma cell
line (data not shown).
Table III Relative ratio of TGF-x contents in paired normal and
malignant tissues of patients
Colon Lung P value
Mean ratio(T/N) 18.67± 11.69 (22) 4.10± 1.02 (15) ¶
or 7.12± 1.84 (21)a ¶
Right colon 4.31 ± 1.78 (8) <000I
Left colon 28.88± 18.21 (14) or 8.84±2.71 (13) 0
T/N>2 55% 67% NS
T/N>4 55% 33% NS
aValues represent the means ± S.E. if the specimen with excessively
highTGF-acontentisexcluded.¶: P<0.001byStudent'st-test,butnot
significant by Wilcoxon rank sum test. NS: not statistically significant.
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Figure 2 The relative increase in the specific content ofTGF-x
in paired tumour versus corresponding normal tissues of patients with colon and lung carcinomas.
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Figure 3 Representative Northern blot hybridisation showing the expression of an approximately 4.8 kb TGF-a mRNA in
normal and cancerous colon and lung tissues.
Discussion
We have confirmed that normal human adult colonic mucosa
contains acid-ethanol extractable immunoreactive TGF-a,
and the level ofTGF-xis higher in the right than left colon.
Cartlidge & Elder (1989) have recently reported that the level
of immunoreactive TGF-o decreased progressively from the
proximal to distal colon, and the levels in ascending and
transverse colon are approximately 2 to 3 times higher than
those found in the descending and sigmoid colon. Our results
also show a two-fold higher TGF-xlevel in mucosa of the
right than left colon. EGF-like activity as detected by the
radioreceptor assay method has also been reported in acetic acid extracts of normal colonic mucosa, and the levels also
varied among individuals (Rothbauer etal., 1989). Since the
level of immunoreactive EGF molecule in acid-ethanol ex-
tracts of human normal colon is very low and does not
appear to vary between the different segments of the colon
(Cartlidge & Elder, 1989), the EGF-binding activity detected428 C. LIU et al.
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Figure 4 The relative expression of TGF-a mRNA in colon
cancer tissues compared to their paired adjacent normal mucosa.
All values have been normalised to the P-actin expression.
by Rothbauer et al. (1989) most likely also represented
TGF-a. We have further demonstrated the presence of the
full-length (4.6-4.8 Kb) TGF-a mRNA species in the total
cellular RNA extracts of normal human colonic mucosa, thus
further confirming the expression of this growth factor in
normal adult colon.
The expression of TGF-at in normal adult lung tissue has
not been previously reported, although Nickell et al. (1983)
have previously indicated its presence using the classical bio-
assay method of detecting TGFs. The mean immunoreactive
TGF-x activity in normal lung parenchyma is comparable to
that found in the colon. In contrast to a previous study
which failed to show the presence of TGF-oc specific mRNA
in normal lungs (Derynck et al., 1987), we have demon-
strated its presence in our study. With the continuing ad-
ditions to the list of normal adult human tissues that express
TGF-x, it appears that the role and importance of TGF-o in
the growth and function of normal human adult tissues,
especially epithelial cells requires re-evaluation.
Expression/secretion of TGF-c has been reported in most
of the human colon carcinoma cell lines studied, but the
levels of expression are highly variable (Anzano et al., 1989;
Coffey et al., 1987a; Watkins et al., 1988; Hanauske et al.,
1987). TGF-a expression in primary human colon carcinoma
tissues has not been adequately reported. Rothbauer et al.
(1989) used a radio-receptor assay method to study EGF-like
activity in extracts of 15 paired normal and carcino-
matous colonic tissues and found that the carcinomas
contained slightly, but significantly, more activity than the
normal mucosa (1.98 ± 0.29 vs 1.38 ± 0.19 ng mg-' protein,
P<0.025). Our results indicate that the mean immuno-
reactive TGF-a activity in cancerous tissue is 4 times higher
than that of the normal mucosa, but when the value for
paired normal and tumour tissues are normalised for each
patient, the average tumour/normal ratio is even higher.
Fifty-five per cent of the colon cancers have a T/N ratio
higher than 4, and interestingly, tumours of the left side of
the colon appear to express higher levels of TGF-a than the
right sided tumours. Unfortunately, when the TGF-a levels
are analysed for their clinical and pathological relevance, no
significant correlation could be found with the stage of the
disease and the grade of the tumour, nor with the degree of
desmoplastic and inflammatory reaction in these tumours.
In contrast with the radio-immunoassay findings, signi-
ficant over-expression of TGF-x mRNA in primary colon
carcinoma tissues is rare. The highest over-expression in
,amour versus normal mucosa is 2- to 3-fold, and this is only
seen in less than 20% of the specimens studied. This is
different from renal cell carcinomas where more than 3-fold
over-expression was found in 50% of cases (Gomella et al.,
1989). The discrepancy between the levels of protein and
mRNA expression could be caused by different post-trans-
criptional controls that exist in normal and neoplastic cells. It
is also possible that in the normal colonic mucosa, most of
the TGF-a is synthesised by the epithelial cells and secreted
into the lumen, hence lower amount is measurable in the
tissue, while most of the TGF-a synthesised by invading
tumour cells is secreted extracellularly and retained within
the tumour tissue, thus yielding a higher specific content.
Carcinomas of the lung appear to express less TGF-o than
those from the colon. The mean TGF-x content for lung
tumours is only 2 times higher than the normal parenchyma,
the mean T/N ratio for paired specimens is 4.1 ± 1.02 (versus
at least 7.12 ± 1.84 for colon), and only 33% of lung car-
cinomas demonstrate a T/N ratio of greater than 4. How-
ever, similar to colon cancers, the TGF-c levels cannot be
correlated to the histological types of tumour, the stage of
the disease, nor the degree of desmoplastic reaction in the
tumours. Bergh (1988) has also reported that expression of
TGF-a alone in non-small cell lung carcinoma cell lines could
not be correlated with the extent of fibrosis in tumours
formed by these cells in nude mice.
TGF-ax has been considered as one of the prototypes of an
autocrine growth factor which may play important roles in
carcinogenesis and tumour growth (Sporn & Todaro, 1980;
Sporn & Roberts, 1985; Goustin et al., 1986; Derynck, 1988).
TGF-a may also play an important role in tumour angio-
genesis (Schreiber et al., 1986), and in the pathogenesis of
paraneoplastic hypercalcaemia (Ibbotson et al., 1986; Tash-
jian et al., 1985). Nonetheless, the importance of TGF-c in
tumour cell biology in vivo remains speculative, and our own
analyses on colon and lung carcinomas have not provided
further insights. Rothbauer et al. reported that in 2 of 3
patients with familial polyposis, the TGF-a levels in either
the preneoplastic adenomatous polyps, or carcinoma, were
actually lower than those in the 'normal' mucosa, suggesting
that TGF-a expression is not related to the mechanism of
multistage carcinogenesis. The introduction and expression of
hTGF-a gene into mouse keratinocytes from normal skin or
papillomas did not result in the formation of carcinoma,
suggesting that this growth factor does not influence tumour
progression directly (Finzi et al., 1988). However, correlation
of TGF-a synthesis or secretion with tumorigenicity and the
pathological stage also cannot be demonstrated in human
breast cancer cell lines/tissues (Dickson et al., 1986; Perro-
teau et al., 1986; Zajchowski et al., 1988; Ciardiello et al.,
1989). The marked heterogeneity of TGF-m expression, even
among cancers of the same organ or histological type, sug-
gests that it is unlikely to play a consistent and direct role in
the pathogenesis of all cancers. However, TGF-o may still
play an important indirect but synergistic role in the tumour
biology of some individual human cancers, especially through
its autocrine effects on cell proliferation and tumour growth
rate, on pericellular matrix proteolysis involving the plas-
minogen activator systems (Laiho & Keski-Oja, 1989), and
through its paracrine effect on angiogenesis (Schreiber et al.,
1986). Further knowledge on the level and pattern of expres-
sion of TGF-x in primary human cancers may also contri-
bute understanding to its future use as a tumour marker
(Yeh et al., 1987; Ciardiello et al., 1989), prognostic indicator
(Arteaga et al., 1988) and therapeutic target (Greig et al.,
1988).
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